Company Announcements
Director/PDMR Shareholding
Related Companies
GlaxoSmithKline plc (the 'Company')
Transaction notification
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
|
a) |
Name |
Sir Andrew Witty |
||||
|
b) |
Position/status |
CEO |
||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
GlaxoSmithKline plc |
||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||
|
b) |
Nature of the transaction |
Sale of Ordinary Shares on 27 July 2016 at a price of £16.9350. |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information
Aggregated volume Price |
n/a (single transaction)
|
||||
|
e) |
Date of the transaction |
2016-07-27 |
||||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
|
a) |
Name |
Mr D S Redfern |
||||
|
b) |
Position/status |
Chief Strategy Officer |
||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
GlaxoSmithKline plc |
||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||
|
b) |
Nature of the transaction |
The exercise of options over 26,800 Ordinary Shares, granted on 20 February 2007 under the GlaxoSmithKline Share Option Plan. |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information
Aggregated volume Price |
n/a (single transaction)
|
||||
|
e) |
Date of the transaction |
2016-07-27 |
||||
|
f) |
Place of the transaction
|
n/a |
||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
|
a) |
Name |
Mr D S Redfern |
||||
|
b) |
Position/status |
Chief Strategy Officer |
||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
GlaxoSmithKline plc |
||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||
|
b) |
Nature of the transaction |
The sale of 26,800 Ordinary Shares following the exercise of options granted on 20 February 2007 under the GlaxoSmithKline Share Option Plan. |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information
Aggregated volume Price |
n/a (single transaction)
|
||||
|
e) |
Date of the transaction |
2016-07-27 |
||||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
|
a) |
Name |
Mr D S Redfern |
||||
|
b) |
Position/status |
Chief Strategy Officer |
||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
GlaxoSmithKline plc |
||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||
|
b) |
Nature of the transaction |
The exercise of options over 24,186 Ordinary Shares, granted on 19 February 2008 under the GlaxoSmithKline Share Option Plan. |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information
Aggregated volume Price |
n/a (single transaction)
|
||||
|
e) |
Date of the transaction |
2016-07-27 |
||||
|
f) |
Place of the transaction
|
n/a |
||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
|
a) |
Name |
Mr D S Redfern |
||||
|
b) |
Position/status |
Chief Strategy Officer |
||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
GlaxoSmithKline plc |
||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||
|
b) |
Nature of the transaction |
The sale of 24,186 Ordinary Shares following the exercise of options granted on granted on 19 February 2008 under the GlaxoSmithKline Share Option Plan. |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information
Aggregated volume Price |
n/a (single transaction)
|
||||
|
e) |
Date of the transaction |
2016-07-27 |
||||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
|
a) |
Name |
Mr D S Redfern |
||||
|
b) |
Position/status |
Chief Strategy Officer |
||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
GlaxoSmithKline plc |
||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||
|
b) |
Nature of the transaction |
The exercise of options over 2,614 Ordinary Shares, granted on 19 February 2008 under the GlaxoSmithKline Share Option Plan. |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information
Aggregated volume Price |
n/a (single transaction)
|
||||
|
e) |
Date of the transaction |
2016-07-28 |
||||
|
f) |
Place of the transaction
|
n/a |
||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
|
a) |
Name |
Mr D S Redfern |
||||
|
b) |
Position/status |
Chief Strategy Officer |
||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
GlaxoSmithKline plc |
||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||
|
b) |
Nature of the transaction |
The sale of 2,614 Ordinary Shares following the exercise of options granted on granted on 19 February 2008 under the GlaxoSmithKline Share Option Plan. |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information
Aggregated volume Price |
n/a (single transaction)
|
||||
|
e) |
Date of the transaction |
2016-07-28 |
||||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
|
a) |
Name |
Ms C Thomas |
||||
|
b) |
Position/status |
Senior Vice President, Human Resources |
||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
GlaxoSmithKline plc |
||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||
|
b) |
Nature of the transaction |
Sale of Ordinary Shares on 28 July 2016 at a price of £16.9757.
|
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information
Aggregated volume Price |
n/a (single transaction)
|
||||
|
e) |
Date of the transaction |
2016-07-28 |
||||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
||||
This information is provided by RNS
You are here: news > regulatory news
10 Lower Thames St,
London EC3R 6EN